4PKB Stock Overview
A clinical-stage immuno-oncology company, focuses on developing cancer treatments. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
LAVA Therapeutics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.50 |
| 52 Week High | US$3.60 |
| 52 Week Low | US$1.39 |
| Beta | 0.48 |
| 11 Month Change | -18.03% |
| 3 Month Change | -6.25% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -87.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4PKB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.3% | 0.8% | 0.8% |
| 1Y | n/a | -18.3% | 8.6% |
Return vs Industry: Insufficient data to determine how 4PKB performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 4PKB performed against the German Market.
Price Volatility
| 4PKB volatility | |
|---|---|
| 4PKB Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4PKB's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 4PKB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 37 | Steve Hurly | www.lavatherapeutics.com |
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer.
LAVA Therapeutics N.V. Fundamentals Summary
| 4PKB fundamental statistics | |
|---|---|
| Market cap | €38.91m |
| Earnings (TTM) | -€23.08m |
| Revenue (TTM) | €7.06m |
5.5x
P/S Ratio-1.7x
P/E RatioIs 4PKB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4PKB income statement (TTM) | |
|---|---|
| Revenue | US$7.40m |
| Cost of Revenue | US$164.00k |
| Gross Profit | US$7.23m |
| Other Expenses | US$31.42m |
| Earnings | -US$24.18m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | 97.78% |
| Net Profit Margin | -326.89% |
| Debt/Equity Ratio | 12.6% |
How did 4PKB perform over the long term?
See historical performance and comparison